Fair question.
Full text of article is available:
https://www.researchgate.net/figure/Models-of-payment-for-the-participation-of-research-subjects_tbl1_7737793
I searched my journal databases and there are just as many articles stating there are numerous disadvantages associated with payment of subjects. Payment is not common practice in Australia; more common in the US. Regardless, payment in Imagion's trial would require a fairly significant trial re-design...
Should we petition Red Cross to enable payment for plasma donations, and the sprog clinics to pay sperm donors also?
- Forums
- ASX - By Stock
- IBX
- Financial incentives for recruiting is not uncommon
Financial incentives for recruiting is not uncommon
-
-
-
Share
I think it's going to be really hard to get a 15 patient cohort without a trial redesign.
And then what about the next step, 300 people? You can understand the markets apprehension.
- There are more pages in this discussion • 13 more messages in this thread...
Featured News
Add IBX (ASX) to my watchlist
|
|||||
Last
3.6¢ |
Change
-0.003(7.69%) |
Mkt cap ! $1.283M |
Open | High | Low | Value | Volume |
3.9¢ | 3.9¢ | 3.6¢ | $835 | 21.75K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 75 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 18056 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 75 | 0.036 |
3 | 144512 | 0.035 |
1 | 42385 | 0.034 |
1 | 10000 | 0.033 |
2 | 163188 | 0.032 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 18056 | 3 |
0.044 | 1422 | 1 |
0.045 | 2730 | 1 |
0.056 | 6320 | 1 |
0.062 | 100138 | 2 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
IBX (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online